Economy

Novartis Multiple Sclerosis Pill Missed Expectations in Key Study

Novartis AG’s experimental multiple sclerosis pill prevented fewer relapses than expected in two late-stage trials, potentially giving its cross-town competitor Roche Holding AG an advantage with a rival drug it’s developing.